These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21251539)

  • 1. Hemoglobin variability as a predictor of mortality: What's a practitioner to do?
    Wish JB
    Am J Kidney Dis; 2011 Feb; 57(2):190-3. PubMed ID: 21251539
    [No Abstract]   [Full Text] [Related]  

  • 2. Facility-level interpatient hemoglobin variability in hemodialysis centers participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Associations with mortality, patient characteristics, and facility practices.
    Pisoni RL; Bragg-Gresham JL; Fuller DS; Morgenstern H; Canaud B; Locatelli F; Li Y; Gillespie B; Wolfe RA; Port FK; Robinson BM
    Am J Kidney Dis; 2011 Feb; 57(2):266-75. PubMed ID: 21251541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemoglobin variability and mortality: confounding by disease severity.
    Weinhandl ED; Peng Y; Gilbertson DT; Bradbury BD; Collins AJ
    Am J Kidney Dis; 2011 Feb; 57(2):255-65. PubMed ID: 20801571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study.
    Fort J; Cuevas X; García F; Pérez-García R; Lladós F; Lozano J; Martín-Malo A;
    Nephrol Dial Transplant; 2010 Aug; 25(8):2702-10. PubMed ID: 20176608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Message to the FDA on ESAs: REMS is not enough, more studies are needed.
    Singh AK
    Clin J Am Soc Nephrol; 2010 Aug; 5(8):1355-8. PubMed ID: 20688885
    [No Abstract]   [Full Text] [Related]  

  • 6. Normalization of hemoglobin in patients with CKD may cause harm: but what is the mechanism?
    Littlewood TJ
    Am J Kidney Dis; 2008 Oct; 52(4):642-4. PubMed ID: 18805344
    [No Abstract]   [Full Text] [Related]  

  • 7. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
    Singh AK
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):553-6. PubMed ID: 20203166
    [No Abstract]   [Full Text] [Related]  

  • 8. Triumph and tragedy: anemia management in chronic kidney disease.
    Novak JE; Szczech LA
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial.
    McMahon LP; Kent AB; Kerr PG; Healy H; Irish AB; Cooper B; Kark A; Roger SD
    Nephrol Dial Transplant; 2010 Mar; 25(3):920-6. PubMed ID: 19906658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of haemoglobin and erythropoietin dose changes on mortality: a secondary analysis of results from a randomized anaemia management trial.
    Lau JH; Gangji AS; Rabbat CG; Brimble KS
    Nephrol Dial Transplant; 2010 Dec; 25(12):4002-9. PubMed ID: 20530806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The KDIGO anemia guideline: can reason triumph over regulation?
    Wish JB
    Nephrol News Issues; 2012 Dec; 26(13):20, 22-3. PubMed ID: 23346853
    [No Abstract]   [Full Text] [Related]  

  • 12. Applying evidence into routine clinical care at a unit level: the exemplar of renal anaemia management.
    Gallagher MP; Cass A; Craig JC
    Nephrology (Carlton); 2010 Jun; 15(4):429-33. PubMed ID: 20609094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survey of attitude of physicians on updates in the management of anemia in chronic kidney disease patients - an eye-opener.
    Binnani PG
    Saudi J Kidney Dis Transpl; 2009 Nov; 20(6):1090. PubMed ID: 19861881
    [No Abstract]   [Full Text] [Related]  

  • 14. Hemoglobin variability in dialysis patients.
    Brimble KS; Clase CM
    J Am Soc Nephrol; 2007 Aug; 18(8):2218-20. PubMed ID: 17627931
    [No Abstract]   [Full Text] [Related]  

  • 15. Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate.
    Agarwal R
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1340-6. PubMed ID: 20448071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?
    Walker RG
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):935-7. PubMed ID: 18579671
    [No Abstract]   [Full Text] [Related]  

  • 17. Stabilizing hemoglobin levels: what's new in IV iron and anemia management?
    Fishbane S; Larson K; VanBuskirk S
    Nephrol Nurs J; 2008; 35(5):493-502. PubMed ID: 18856080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial perspective. Should hemoglobin targets for anemic patients with chronic kidney disease be changed?
    Parfrey PS
    Am J Nephrol; 2010; 31(6):565-6. PubMed ID: 20501992
    [No Abstract]   [Full Text] [Related]  

  • 19. Debate: CON Position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed?
    Locatelli F; Del Vecchio L
    Am J Nephrol; 2010; 31(6):557-60; discussion 561-2. PubMed ID: 20501989
    [No Abstract]   [Full Text] [Related]  

  • 20. Tips for erythropoiesis-stimulating agent treatment of renal anemia.
    Tomosugi N; Koshino Y
    Clin Exp Nephrol; 2020 Jan; 24(1):105-106. PubMed ID: 31617026
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.